Department of Hematology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Drug Development Department, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Cancer Med. 2020 Jun;9(11):3725-3732. doi: 10.1002/cam4.2796. Epub 2020 Apr 6.
In patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL), one course of low-dose radiotherapy (LD-RT) 2 × 2 Gy is emerging as new option of therapy in palliative setting. Efficacy of LD-RT when repeated remains to be determinate. This study aims to assess the efficacy of repeated LD-RT given in patients with indolent B-NHL.
All consecutive adult patients who received two or more courses of LD-RT 2 × 2 Gy for indolent B-NHL at Gustave Roussy institution, during the period 1990-2015 were retrospectively investigated.
Thirty-three patients received two or more courses of LD-RT for indolent B-NHL during the study period. The median age was 57 (range 37-80) years, histological types were distributed among follicular lymphoma (n = 24 pts; 73%), marginal-zone lymphoma (n = 6 pts; 18%), and primary cutaneous follicle center lymphoma (n = 3 pts; 9%). The median number of low-dose radiation therapy courses given per patients was 2 (range 2-6). The overall response rates following the first and the second course of LD-RT were 96% and 88%, respectively (P = .31). The 1- and 2-years local control rates following the first courses of LD-RT were 94% (CI 95: 86-100) and 94% (CI 95: 86-98); and were 91% (CI 95: 82-100) and 88% (CI 95: 77-100) following the second course of LD-RT (P = .39).
The repeated courses of LD-RT offered similar efficacy compare with the first course in patients with indolent B-NHL. LD-RT repeated is a simple, easy to give, and non-toxic asset that could be investigated as treatment option in patients with indolent B-NHL.
在惰性 B 细胞非霍奇金淋巴瘤（B-NHL）患者中，低剂量放疗（LD-RT）2×2 Gy 作为一种新的姑息治疗选择正在出现。重复 LD-RT 的疗效仍有待确定。本研究旨在评估在惰性 B-NHL 患者中重复给予 LD-RT 的疗效。
回顾性调查了 1990 年至 2015 年期间在 Gustave Roussy 机构接受两次或两次以上 LD-RT 2×2 Gy 治疗的连续成年惰性 B-NHL 患者。
在研究期间，33 名患者接受了两次或两次以上的 LD-RT 治疗。中位年龄为 57 岁（范围 37-80 岁），组织学类型分布为滤泡性淋巴瘤（n=24 例；73%）、边缘区淋巴瘤（n=6 例；18%）和原发性皮肤滤泡中心淋巴瘤（n=3 例；9%）。每位患者接受的低剂量放疗疗程中位数为 2（范围 2-6）。首次和第二次 LD-RT 后的总体缓解率分别为 96%和 88%（P=.31）。首次 LD-RT 后 1 年和 2 年的局部控制率分别为 94%（CI 95%：86-100）和 94%（CI 95%：86-98）；第二次 LD-RT 后 1 年和 2 年的局部控制率分别为 91%（CI 95%：82-100）和 88%（CI 95%：77-100）（P=.39）。
在惰性 B-NHL 患者中，重复 LD-RT 疗程与首次疗程疗效相当。重复 LD-RT 是一种简单、易于实施且无毒的治疗方法，可作为惰性 B-NHL 患者的治疗选择进行研究。
